Vedroprevir
Vedroprevir (GS-9451) is an inhibitor for HCV NS3/4A protease with an IC50 of 3.2 nM. Vedroprevir is also an inhibitor for breast cancer resistant protein (BCRP) with an IC50 of 1.4 μM. Vedroprevir inhibits P-gp, MRP1 and MRP2 with IC50 of 34, 14.9 and 12 μM, respectively. Vedroprevir exhibits good pharmacokinetic characteristics in rats and dogs.
For research use only. We do not sell to patients.
- CAS No.: 1098189-15-1
- Formula: C45H60ClN7O9S
- Molecular Weight:910.52
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
IC50: 3.2 nM (HCV NS3/4A protease), 1.4 μM (BCRP), 34 μM (P-gp), 14.9 μM (MRP1), 12 μM (MRP2)
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1098189-15-1
-
Molecular Weight 910.52
-
Formula C45H60ClN7O9S
-
SMILES
O=C([C@H]1N(C[C@@H](C1)OC2=CC(C3=CSC(NC(C)C)=N3)=NC4=C2C=CC(OCCN5CCOCC5)=C4Cl)C([C@H](C(C)(C)C)NC(O[C@H]6C[C@]7([H])[C@](C7)([H])C6)=O)=O)N[C@]8([C@@H](C8)CC)C(O)=O
-
Synonyms
GS-9451
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)